Time to Panic About Merck's Patent Expirations?

Many big pharmaceutical companies managed to weather the recent flurry of patent expirations that affected their top lines. Merck , a Dow component and one of the planet's largest drugmakers, was hit hard by the loss of exclusivity for its multibillion-dollar drug Singulair, and it now relies on blockbuster drugs Januvia and Janumet. But will the big pharma have to deal with more patent expirations in the coming years? In the following video, analysts David Williamson and Max Macaluso focus on the drugs that Merck stands to lose protection on in the coming years.

Dividend stocks to watch today
Dividend stocks can make you rich. It's as simple as that. While they don't garner the notoriety of high-flying growth stocks, they're also less likely to crash and burn. And over the long term, the compounding effect of the quarterly payouts, as well as their growth, adds up faster than most investors imagine. With this in mind, our analysts sat down to identify the absolute best of the best when it comes to rock-solid dividend stocks, drawing up a list in this free report of nine that fit the bill. To discover the identities of these companies before the rest of the market catches on, you can download this valuable free report by simply clicking here now.

The article Time to Panic About Merck's Patent Expirations? originally appeared on Fool.com.

David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Can't get enough business news?

Sign up for Finance Report by AOL and get everything from retailer news to the latest IPOs delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.